Medistim Dirección

Dirección controles de criterios 2/4

El CEO de Medistim's es Kari Krogstad , nombrado en Sep 2009, tiene una permanencia de 14.58 años. compensación anual total es NOK7.21M, compuesta por 42% salario y 58% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.39% de las acciones de la empresa, por valor de NOK12.42M. La antigüedad media del equipo directivo y de la junta directiva es de 9.3 años y 2 años, respectivamente.

Información clave

Kari Krogstad

Chief Executive Officer (CEO)

kr7.2m

Compensación total

Porcentaje del salario del CEO	42.0%
Permanencia del CEO	14.7yrs
Participación del CEO	0.4%
Permanencia media de la dirección	9.4yrs
Promedio de permanencia en la Junta Directiva	1.3yrs

Actualizaciones recientes de la dirección

Recent updates

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 04

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Mar 19

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Mar 02

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Feb 19

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital

Jan 21

Have Insiders Been Selling Medistim ASA (OB:MEDI) Shares?

Dec 27

Medistim (OB:MEDI) Has Rewarded Shareholders With An Exceptional 375% Total Return On Their Investment

Dec 10

Could The Market Be Wrong About Medistim ASA (OB:MEDI) Given Its Attractive Financial Prospects?

Nov 23

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kari Krogstad en comparación con los beneficios de Medistim?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	kr103m
Dec 31 2023	kr7m	kr3m	kr104m
Sep 30 2023	n/a	n/a	kr117m
Jun 30 2023	n/a	n/a	kr116m
Mar 31 2023	n/a	n/a	kr116m
Dec 31 2022	kr9m	kr3m	kr114m
Sep 30 2022	n/a	n/a	kr98m
Jun 30 2022	n/a	n/a	kr92m
Mar 31 2022	n/a	n/a	kr93m
Dec 31 2021	kr6m	kr3m	kr91m
Sep 30 2021	n/a	n/a	kr88m
Jun 30 2021	n/a	n/a	kr84m
Mar 31 2021	n/a	n/a	kr70m
Dec 31 2020	kr6m	kr3m	kr69m
Sep 30 2020	n/a	n/a	kr71m
Jun 30 2020	n/a	n/a	kr74m
Mar 31 2020	n/a	n/a	kr75m
Dec 31 2019	kr4m	kr3m	kr70m
Sep 30 2019	n/a	n/a	kr79m
Jun 30 2019	n/a	n/a	kr73m
Mar 31 2019	n/a	n/a	kr64m
Dec 31 2018	kr4m	kr2m	kr57m
Sep 30 2018	n/a	n/a	kr46m
Jun 30 2018	n/a	n/a	kr48m
Mar 31 2018	n/a	n/a	kr45m
Dec 31 2017	kr4m	kr2m	kr48m

Compensación vs. Mercado: La compensación total de Kari($USD662.98K) está por encima de la media de empresas de tamaño similar en el mercado Norwegian ($USD497.38K).

Compensación vs. Ingresos: La compensación de Kari ha sido consistente con los resultados de la empresa en el último año.

CEO

Kari Krogstad (59 yo)

14.7yrs

Permanencia

kr7,205,702

Compensación

Ms. Kari Eian Krogstad serves as Independent Director at Vistin Pharma ASA since June 24, a2020. She has been the Chief Executive Officer of Medistim ASA since September 1, 2009 and serves as its President...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kari Krogstad	CEO & President	14.7yrs	kr7.21m	0.39% NOK 12.5m
Thomas Jakobsen	Chief Financial Officer	no data	kr2.77m	0.17% NOK 5.4m
Helge Borslid	Vice President of Operations & Manufacturing	no data	kr1.67m	sin datos
Hæge Johanne Wetterhus	Vice President of Marketing	13.8yrs	kr1.87m	0.0087% NOK 280.9k
Hakon Grothe	Chief Innovation Officer	5.1yrs	kr1.91m	0.043% NOK 1.4m
Ole Eiksund	Chief Business Development Officer	2.1yrs	kr1.68m	0.032% NOK 1.0m
Mike Farbelow	President of Medistim USA Inc	no data	kr3.63m	0.011% NOK 351.4k
Roger Morberg	Vice President of Sales - APAC	no data	kr2.55m	0.089% NOK 2.9m
Stephanie Stenhagen	Vice President of Sales EMEA	no data	kr1.79m	0.015% NOK 491.3k
Ole Robsrud	Managing Director of Medistim Norge AS	no data	kr1.83m	0.019% NOK 607.4k

9.4yrs

Permanencia media

59yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MEDI es experimentado (9.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Oyvin Broymer	Chairman	24.3yrs	kr495.00k	7.02% NOK 226.8m
Anna Ahlberg	Independent Director	1.1yrs	sin datos	sin datos
Jon Hoem	Independent Director	1.3yrs	sin datos	sin datos
Ole Dahlberg	Independent Director	1.1yrs	sin datos	sin datos
Tove Raanes	Independent Director	10.3yrs	kr300.00k	sin datos

1.3yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de MEDI no se considera experimentada (2 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Medistim Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Medistim ASA Announces Board Changes

CEO & President recently bought kr1.9m worth of stock

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

Independent Director recently bought kr301k worth of stock

Independent Director recently bought kr104k worth of stock

Recent updates

Medistim ASA Approves Dividend for the Year 2023, Payable on May 6, 2024

Medistim ASA Proposes Dividend

Medistim ASA Announces Board Changes

Medistim ASA Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2023 earnings released: EPS: kr5.68 (vs kr6.25 in FY 2022)

CEO & President recently bought kr1.9m worth of stock

Medistim ASA to Report Q1, 2024 Results on Apr 25, 2024

One Medistim ASA (OB:MEDI) Analyst Has Been Cutting Their Forecasts

Price target decreased by 10% to kr260

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: kr1.80 (vs kr1.82 in 2Q 2022)

CEO & President recently sold kr10.0m worth of stock

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr1.41 (vs kr1.30 in 1Q 2022)

Upcoming dividend of kr4.50 per share at 1.6% yield

Independent Director recently bought kr301k worth of stock

Consensus EPS estimates increase by 23%

Full year 2022 earnings released: EPS: kr6.25 (vs kr4.99 in FY 2021)

Danske Bank A/S acquired a 5% stake in Medistim ASA.

Medistim ASA to Report First Half, 2023 Results on Aug 31, 2023

What Does Medistim ASA's (OB:MEDI) Share Price Indicate?

Third quarter 2022 earnings: Revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Should You Be Adding Medistim (OB:MEDI) To Your Watchlist Today?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to kr300

A Look At The Intrinsic Value Of Medistim ASA (OB:MEDI)

Investor sentiment improved over the past week

Consensus EPS estimates increase by 12%

First quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of kr3.75 per share

Medistim (OB:MEDI) Is Increasing Its Dividend To kr3.75

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Medistim ASA Proposes Ordinary Dividend for 2021, Payable on 9 May 2022

Medistim (OB:MEDI) Is Paying Out A Larger Dividend Than Last Year

Investor sentiment deteriorated over the past week

Statutory Profit Doesn't Reflect How Good Medistim's (OB:MEDI) Earnings Are

Consensus EPS estimates fall by 20%

Medistim's (OB:MEDI) Shareholders Will Receive A Bigger Dividend Than Last Year

Independent Director recently bought kr104k worth of stock

Price target decreased to kr343

Medistim ASA Proposes Dividend

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

CEO & President recently bought kr4.4m worth of stock

Medistim (OB:MEDI) Is Reinvesting To Multiply In Value

Third quarter 2021 earnings released: EPS kr1.03 (vs kr0.79 in 3Q 2020)

Medistim (OB:MEDI) Might Become A Compounding Machine

Here's Why I Think Medistim (OB:MEDI) Might Deserve Your Attention Today

Second quarter 2021 earnings released: EPS kr1.88 (vs kr1.11 in 2Q 2020)

Chief Financial Officer recently sold kr6.6m worth of stock

Medistim ASA Announces the Launch of the Pay Per Procedure Functionality to Latest MiraQTM Platform in the US Market

Here's What Medistim's (OB:MEDI) Strong Returns On Capital Mean

First quarter 2021 earnings released: EPS kr1.20 (vs kr1.16 in 1Q 2020)

Medistim ASA Approves Dividend, Payable on May 7, 2021

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Chairman recently sold kr179m worth of stock

Is Medistim ASA's(OB:MEDI) Recent Stock Performance Tethered To Its Strong Fundamentals?

Medistim ASA (OB:MEDI) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target raised to kr245

Full year 2020 earnings released: EPS kr3.81 (vs kr3.87 in FY 2019)

Revenue beats expectations, earnings disappoint

Here's What You Should Know About Medistim ASA's (OB:MEDI) 1.1% Dividend Yield

Universal-Investment-Luxembourg SA acquired a 5.07% stake in Medistim ASA (OB:MEDI).

New 90-day high: kr270

A Look Into Medistim's (OB:MEDI) Impressive Returns On Capital